Cytokinetics Appoints James Daly to Board with Commercialization Expertise.

Cytokinetics has appointed James M. Daly to its Board of Directors, bringing over 30 years of global biopharmaceutical leadership experience, particularly in commercialization. Daly previously served as Chief Commercial Officer at Incyte Corporation, where he led the launch of Jakafi and oversaw global commercial capabilities. He joins Cytokinetics as the company advances towards becoming a fully integrated commercial organization.

Cytokinetics, Incorporated (Nasdaq: CYTK) has announced the appointment of James M. Daly to its Board of Directors, effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience, particularly in commercialization, to the company's Board. He previously served as the Chief Commercial Officer at Incyte Corporation, where he led the launch of Jakafi® (ruxolitinib) and oversaw the development of the company's global commercial capabilities [1].

Before joining Incyte, Mr. Daly spent 10 years at Amgen, holding multiple senior leadership positions, including Senior Vice President of North America Commercial Operations. During his tenure, he successfully launched several medicines, including Neulasta®, Xgeva®, Nplate®, and Vectibix® [2]. He began his career at GlaxoSmithKline and earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, SUNY [1].

Cytokinetics, a specialty cardiovascular biopharmaceutical company, is building on its over 25 years of scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. The company is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from the pivotal Phase 3 clinical trial SEQUOIA-HCM in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM [1].

Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten, a cardiac myosin inhibitor with a distinct mechanism of action from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF), and CK-089, a fast skeletal muscle troponin activator with potential therapeutic applications to specific types of muscular dystrophy and other conditions of impaired skeletal muscle function [1].

The appointment of Mr. Daly is part of Cytokinetics' strategic move towards becoming a fully integrated commercial organization. His extensive experience in commercializing innovative therapies and guiding later-stage, global biopharma companies is expected to contribute significantly to the company's growth and success [1].

References:
[1] https://www.marketscreener.com/news/cytokinetics-names-jim-daly-to-board-of-directors-ce7c51d2dd80f626
[2] https://www.globenewswire.com/news-release/2025/08/20/3136325/35409/en/Cytokinetics-Names-Jim-Daly-to-Board-of-Directors.html